Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
23.63
+1.44 (6.49%)
At close: Dec 5, 2025, 4:00 PM EST
23.23
-0.40 (-1.69%)
After-hours: Dec 5, 2025, 7:59 PM EST
Apellis Pharmaceuticals Employees
As of December 31, 2024, Apellis Pharmaceuticals had 710 total employees, including 705 full-time and 5 part-time employees. The number of employees increased by 4 or 0.57% compared to the previous year.
Employees
710
Change (1Y)
4
Growth (1Y)
0.57%
Revenue / Employee
$1,431,545
Profits / Employee
$63,361
Market Cap
2.99B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
APLS News
- 2 days ago - The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN - GlobeNewsWire
- 2 days ago - Apellis Pharmaceuticals, Inc. (APLS) Presents at Evercore 8th Annual Healthcare Conference Transcript - Seeking Alpha
- 3 days ago - Apellis Pharmaceuticals, Inc. (APLS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 11 days ago - Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 23 days ago - Apellis Pharmaceuticals, Inc. (APLS) Presents at Stifel 2025 Healthcare Conference Transcript - Seeking Alpha
- 24 days ago - Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years - GlobeNewsWire
- 4 weeks ago - Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Apellis Pharmaceuticals, Inc. (APLS) Q3 2025 Earnings Call Transcript - Seeking Alpha